SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Business
Trials and Capital: Women’s Health and APAC’s Healthcare Revolution
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.
January 2, 2025
 · 
1 min read
 · 
Lori Ellis
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Alzheimer’s disease
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval in the second half of 2025.
January 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Collage showing hands holding a light bulb
Career Advice
Computational Biology, Data Science Hot Areas for Oncology R&D Hiring
As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.
January 2, 2025
 · 
5 min read
 · 
Angela Gabriel
Business people shaking hand in China.
Antibody drug conjugate
Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.
January 2, 2025
 · 
2 min read
 · 
Annalee Armstrong
Traffic light in green color, with the dusk sky in the background.
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
 · 
2 min read
 · 
Kate Goodwin
Right and left sides of the brain/iStock, Warrenra
Depression
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.
January 2, 2025
 · 
2 min read
 · 
Heather McKenzie
Sangamo's headquarters in Silicon Valley
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
 · 
2 min read
 · 
Nick Paul Taylor
As a result of the economic problems, the company lacked liquidity and closed down
Layoffs
Layoffs Continued Across Biopharma in 2024
While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.
December 31, 2024
 · 
130 min read
 · 
BioSpace Editorial Staff
Pictured: A scientist works behind an FDA sign/Tay
FDA Tracker
2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval
Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.
December 24, 2024
 · 
223 min read
 · 
BioSpace Editorial Staff
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS